Research Papers:

Chemotherapy-induced uridine diphosphate release promotes breast cancer metastasis through P2Y6 activation

Xiaobin Ma, Xinhua Pan, Yinglei Wei, Binhe Tan, Linli Yang, Hua Ren, Min Qian and Bing Du _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:29036-29050. https://doi.org/10.18632/oncotarget.8664

Metrics: PDF 1371 views  |   HTML 2567 views  |   ?  


Xiaobin Ma1, Xinhua Pan1, Yinglei Wei1, Binhe Tan1, Linli Yang1, Hua Ren1, Min Qian1, Bing Du1

1Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China

Correspondence to:

Bing Du, email: [email protected]

Keywords: UDP, P2Y6, MMP-9, metastasis, breast cancer

Received: November 30, 2015     Accepted: March 28, 2016     Published: April 09, 2016


Although purinergic signaling is important in regulation of immune responses, the therapeutic potential of it in the tumor microenvironment is little defined. In this study, we demonstrate that UDP/P2Y6 signaling facilitates breast cancer metastasis both in vitro and in vivo. We found that P2Y6 is not only aberrantly expressed and mutated in most tumor types, but also highly correlated with poor prognosis in breast cancer patients. Furthermore, the migration and invasion of breast cancer cells was obviously increased by UDP and blocked by P2Y6 specific inhibitor MRS2578 and P2Y6 shRNA. Similar results was also found in breast cancer cell metastasis mouse model. Interestingly, the endogenous agonist UDP was released significantly by doxorubicin treated cells. In addition, the expression and enzyme activity of MMP-9 were both promoted by UDP and inhibited by MRS2578 or P2Y6 shRNA. Furthermore, UDP-induced cell invasion was blocked by an MMP-9 inhibitor. Mechanistically, the MAPKs and NF-κB signaling pathways, known to be involved in regulation of MMP-9 expression, were both activated by UDP. Taken together, our study reveals a relationship between extracellular danger signals and breast cancer metastasis, which suggests the potential therapeutic significance of UDP/P2Y6 signaling in cancer therapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8664